Search results

Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.

Result type

Technology appraisal guidance

Published

20 August 2025

Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

Result type

Interventional procedures guidance

Published

26 February 2014

Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

Result type

Interventional procedures guidance

Published

26 April 2012

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

Result type

Technology appraisal guidance

Published

22 August 2018

This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Published

7 December 2021

Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.

Result type

Technology appraisal guidance

Published

20 March 2019

Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

15 June 2021

Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

Result type

Technology appraisal guidance

Published

28 June 2017

Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

15 January 2025

Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

Result type

Technology appraisal guidance

Published

22 June 2022

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.

Result type

HealthTech guidance

Published

7 August 2013

Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

Result type

Technology appraisal guidance

Published

20 September 2023

Evidence-based recommendations on nivolumab (Opdivo) for advanced non-squamous non-small-cell lung cancer in adults after chemotherapy.

Result type

Technology appraisal guidance

Published

7 July 2021

NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

Result type

Medtech innovation briefing

Published

11 October 2019

This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Published

27 February 2014